5 results
The main objective of this study is to test the effects of combined SGLT1 and SGLT2 inhibition with sotagliflozin on hemoconcentration and plasma volume in patients with heart failure.
Primary Objective:* To evaluate the safety of TAK-164 and to determine the MTD and/or RP2D.Part C (imaging substudy) secondary objectives are:* To determine the biodistribution of 89Zr-TAK-164 in patients with mCRC and/or metastatic gastric…
The main objectives of the study are to demonstrate whether sotagliflozin reduces the composite of CV (cardiovascular) death and HHF (hospitalization for heart failure) as compared to placebo in diabetic patients after admission for WHF (worsening…
This study is designed to demonstrate the CV and renal effects of sotagliflozin in patients with T2D, high CV risk, and moderate renal impairment. One of the major objectives of this study is to fulfill the regulatory mandate that any new therapy…
The aim of this phase 2 study is to investigate the safety and efficacy of dazucorilant in the target ALS patient population.